12/20/2012 9:44:43 AM
SAN DIEGO--(BUSINESS WIRE)--Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases and Quest Diagnostics (NYSE: DGX) and its subsidiary Berkeley HeartLab, announced today an agreement under which both Quest and Berkeley HeartLab will offer ST2 testing services based on Critical Diagnostics’ Presage ST2 Assay. Critical Diagnostics has also signed an agreement with Laboratory Corporation of America (NYSE: LH), better known as LabCorp, to offer testing of the Presage ST2 Assay. Combined, these two diagnostic market leaders perform some one-and-a-half million tests per day.
comments powered by